OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Industry Outlook 2025: A Busy Time Ahead
In an interview with Pharmaceutical Technology®, Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
According to Tore Bergsteiner, managing director and partner at MAIN5, a European consulting firm specializing in digitally enabled change for life sciences R&D organizations, the mega trends from 2024, such as the digital transformation, supply chain globalization, and regulatory reforms, will continue to keep the industry busy in 2025. Industry hasn’t quite matured enough yet, he stresses, and is still getting to grips with how each of the mega trends will have an impact in the future.
“Breaking it down into operations, AI [artificial intelligence]-driven drug discovery or development will be tremendously accelerated and [enable the] identification of potential new drug candidates by analyzing vast amount of data sets, predicting drug efficacy, and optimizing clinical trial designs,” Bergsteiner says. “This approach [will] reduce time and costs associated with traditional drug development.”
There have already been successes with AI-approaches seen in the field of personalized drugs, Bergsteiner adds. “The human metabolism is so different between patients,” he explains, “but AI enables us to develop treatments tailored to individual genetic profiles, improving therapeutic efficiency, efficacy, [and] reducing adverse reactions.”
Click above to watch the full interview
About the speaker
Tore Bergsteiner is Managing Director and Partner at MAIN5, a European consulting firm specializing in digitally enabled change for life sciences R&D organizations. Tore has approximately 30 years of experience in industry and has been a pioneering influence in the field of electronic regulatory submissions and within the management and publishing servicing industry. He previously worked for EXTEDO GmbH, a leading international product vendor of electronic approval systems for publicly owned and private pharmaceutical industry, and IABG GmbH, a major German technology and operating company. Tore graduated in Computer Sciences in 1996 and studied at the University of Bremen, Germany, the University of Texas, Austin, USA, and the Julius Maximilian University of Würzburg, Germany.
